Clinical Trials
Phase 1b/2 Trial of AMXT 1501 and DFMO in Combination With Standard Therapies in Patients with Advanced Solid Tumors Including Breast Cancer and Metastatic Melanoma
aminextx.comCrawled Oct 29, 2026
Phase 1b/2 Trial of AMXT 1501 and DFMO in Combination With Standard Therapies in Patients with Advanced Solid Tumors Including Breast Cancer and Metastatic Melanoma
Polyamines, required for cell growth, are overproduced by cancer cells to evade the immune system and increase myeloid-derived suppressor cells (MDSCs) in tumors.
Note: The name of Aminex’s combination drug changed from PaBT to AMXT 1501/DFMO in August 2015. Earlier publications use the previous name, PaBT or Polyamine-Blocking Therapy. It was changed to AMXT 1501/DFMO to be more consistent with drug-naming convention. The drug itself is unchanged.
Polyamine depletion therapy represents a unique cancer immunotherapy approach
Aminex Therapeutics completed a $4 million Series A financing in 2015, adding 15 new shareholders and appointing Stacy Hock and Rhonda Rhyne to its board.
New findings published in Science Translational Medicine Journal
A peer-reviewed report in *Molecular Oncology* confirms that AMXT 1501 combined with DFMO disrupts the polyamine pathway in neuroblastoma, a cancer dependent on polyamines for growth.
Combination treatment eradicates DIPG cancer in tumor cell lab models
Jim joined Aminex in 2012 after managing NASA’s Apollo lunar landing program and holding leadership roles in electronics, infrastructure, and biotech.
Dr. Burns founded Aminex and led the discovery of its AMXT 1501/DFMO assets over 20 years in biotechnology, holding 15 U.S. patents and publishing 21 scientific papers.
Philippe Bey, PhD, serves as senior VP of R&D at Thrasos Therapeutics and previously held leadership roles at ArQule and Hoechst Marion Roussel (now Sanofi).
Dr. Lewis is a physician-scientist with experience at Harvard Medical School, Stanford Medical School, Syntex Corp, and Aventis Pharmaceuticals, specializing in immunology and cell biology.
With an intense, singular focus, Aminex has advanced AMXT 1501+ DFMO through target discovery, patenting, pre-clinical research and now into clinical development for the potential benefit of cancer patients.
Aminex Therapeutics’ approach reduces polyamine uptake and production in cancer cells, lowering MDSCs and activating the immune system to target solid tumors.
Aminex Therapeutics secures its second FDA orphan drug designation for **AMXT 1501**, a metabolic-targeted therapy aimed at treating **malignant glioma**, including **diffuse intrinsic pontine glioma (DIPG)**—a highly aggressive childhood brain cancer. The company specializes in developing novel treatments for both adult and pediatric brain tumors. This designation follows prior validation for another indication in the same disease category.
Aminex Therapeutics begins a Phase 1b/2 trial testing **AMXT 1501** and **DFMO** to inhibit the polyamine pathway in patients with metastatic melanoma and breast cancer. The study explores potential therapeutic effects for advanced-stage cancers, including melanoma, which dermatologists may encounter in clinical practice. Early findings could inform treatment strategies for resistant tumors.
Aminex Therapeutics activates multiple clinical trial sites for its Phase 1b/2 study of a novel therapy targeting polyamine production in tumors. The treatment aims to inhibit tumor growth and immune suppression by disrupting polyamine pathways critical for cancer cell proliferation. This marks a key development in the company’s pipeline of oncology-focused investigational drugs.
The **Beat Childhood Cancer Research Consortium** at **Penn State College of Medicine** and **Aminex Therapeutics** are initiating a **national clinical trial** for pediatric patients with **high-risk cancers**. The trial aims to evaluate new treatment approaches for children facing aggressive forms of the disease. Researchers and the biotech company collaborate to advance therapeutic options in pediatric oncology.
Aminex Therapeutics secures FDA Orphan Drug Designation for **AMXT 1501** combined with **DFMO** to treat **neuroblastoma**, a rare and aggressive pediatric cancer. The designation accelerates development for therapies targeting underserved patient populations. The company specializes in novel treatments for rare and difficult-to-treat cancers.